COEP - NASDAQ

Coeptis Therapeutics, Inc.

COEP·NASDAQ

$16.40

+0.0000%

HealthcareBiotechnology

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$57.63M

EPS-2.8100

P/E Ratio-5.84

Earnings Date06/03/2026

coep

Income Before Tax

Last Annual Value

-12.28M

3-Year CAGR

31%

5-Year CAGR

-6%

10-Year CAGR

-19%

Adjust for Inflation

Coeptis Therapeutics, Inc. Competitors Analysis of Income Before Tax

COEP · NASDAQ

Company	Income Before Tax	CAGR 3Y	CAGR 5Y	CAGR 10Y
Coeptis Therapeutics, Inc. NASDAQ:COEP	-12.28M	N/A	N/A	N/A
Century Therapeutics, Inc. NASDAQ:IPSC	-9.65M	N/A	N/A	N/A
NRx Pharmaceuticals, Inc. NASDAQ:NRXP	-28.62M	N/A	N/A	N/A
Outlook Therapeutics, Inc. NASDAQ:OTLK	-63976.69B	N/A	N/A	N/A
Equillium, Inc. NASDAQ:EQ	-22.40M	N/A	N/A	N/A
Cue Biopharma, Inc. NASDAQ:CUE	-26.10M	N/A	N/A	N/A
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV	-77.91M	N/A	N/A	N/A
Fortress Biotech, Inc. NASDAQ:FBIO	-33.53M	N/A	N/A	N/A
Mersana Therapeutics, Inc. NASDAQ:MRSN	-68.77M	N/A	N/A	N/A
Karyopharm Therapeutics Inc. NASDAQ:KPTI	-196.00M	N/A	N/A	N/A
OS Therapies Incorporated NYSE:OSTX	-8.88M	N/A	N/A	N/A

Coeptis Therapeutics, Inc. Fair Value Envelope

COEP · NASDAQ

Our analysis suggests that COEP has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.4, this represents a potential HIDDEN relative to our calculated worth for Coeptis Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $16.4

Related Guides

Blog Categories

Continue your COEP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.